A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was: Does the use of thiopental provide added cerebral protection during deep hypothermic circulatory arrest (DHCA)? Altogether, more than 62 papers were found using the reported search, of which 7 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. Four of the seven papers used thiopental alongside other neuroprotective methods and agents. The methods included the use of ice packs to the head and core systemic hypothermia. Agents used alongside thiopental included nicardipine and mannitol. Thiopental was found to have the ability to lower oxygen consumption, where oxygen consumption was measured using the phosphocreatinine and adenosine triphosphate ratio. The neuroprotective effect of thiopental was evaluated by assessing the electrical activity of the brain during circulatory arrest, by which it was shown to be advantageous. However, other trials suggested that adding thiopental during circulatory arrest did not provide any extra protection to the brain. The timing of thiopental administration is of importance in order to gain positive outcomes, as it's ability to lower the cerebral energy state may result in unfavourable results if added before hypothermic circulatory arrest, where this may lead to an ischaemic event. We conclude that the use of thiopental during deep hypothermic circulatory arrest is beneficial, but if administered too early, it may replete the cerebral energy state before arrest and prove to be detrimental.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] .
THREE-PART QUESTION

In [ patients undergoing deep hypothermic circulatory arrest] does [the use of thiopental] [ provide added cerebral protection]?
CLINICAL SCENARIO
A 47-year old in-patient scheduled to undergo an elective aortic aneurysm repair develops a sudden intense pain in his back, then collapses. He is taken into theatre for an urgent aortic repair of a ruptured aortic aneurysm. This requires the use of deep hypothermic circulatory arrest (DHCA); should you use thiopental to provide additional cerebral protection for this patient? The study was small and not randomized consumption and produces an isoelectric electroencephalogram (EEG) [4, 5] .
Continued
Finally, although there is evidence that the use of thiopental provides cerebral protection, the timing of thiopental administration is crucial as it lowers the cerebral energy state when added before circulatory arrest. This may prove detrimental to the brain [6] .
Appoo et al. [2] reviewed the records of 50 consecutive patients who underwent cardiovascular surgery requiring DHCA. Thiopental was used for cerebral protection, as well as ice packs to the head and systemic core hypothermia. The mortality rate was 8%.
Hirotani et al. [3] analysed the neurological complications and evaluated the effects of neuroprotective measures for 75 consecutive patients who underwent aortic arch repair under DHCA. The protective measures were the use of thiopental (15 or 30 mg/kg), nicardipine (20 mg) and mannitol (300 ml). A 10.7% rate of death was observed during the operation, and 6 patients suffered from neural deficits. Hirotani et al. concluded that the use of this mix of agents for cerebral protection is effective for prolonged hypothermic circulatory arrest (HCA).
In an earlier study, Hirotani et al. [4] also reviewed 50 patients who underwent aortic arch repair under HCA. EEG and the partial pressures of oxygen in the internal jugular vein (PjO 2 ) were monitored before and after the administration of thiopental. The PjO 2 increased significantly, showing that thiopental lowers the oxygen used by the brain.
Rung et al. [5] evaluated the effect of hypothermia only and hypothermia plus thiopental on the EEG of 15 infants. The results suggested that cerebral metabolic activity may not be fully suppressed using hypothermia only, and the addition of thiopental is effective in producing an isoelectric EEG.
Siegman et al. [6] administered a bolus of sodium thiopental (40 mg/kg) into sheep during cardiopulmonary bypass (CPB) at 37°C and then an infusion of 3.3 mg/kg/min until HCA. Another group of sheep (control) received no barbiturate. The phosphocreatinine (PCr)/adenosine triphosphate (ATP) ratio was used to measure the tissue energy state. Overall, the PCr/ATP ratio was lower in the treated animals than in the control group. This suggests that administering thiopental before HCA may be harmful as it lowers the energy state of the brain, when the brain is preparing for the period of arrest.
Dewhurst et al. [7] posted a survey to the members of the Association of Cardiothoracic Anaesthetists to find out which pharmacological agents are currently used for cerebral protection during DHCA. Sixty percent (190 of 338) of the members replied. Of the respondents, 59% used thiopental. Sufficient evidence was not gathered to set guidelines on the best pharmacological agent (s) to be used for cerebral protection.
Astrup et al. [8] studied the effect of temperature, 160 mg/kg lidocaine and 40 mg/kg thiopental on cellular potassium in the cerebral cortex during cerebral ischaemia. Potassium efflux rate was reduced by 50% at 28°C and by 25% at 18°C in hypothermia. This was reduced by a further 50% when lidocaine was added. However, no change was observed once thiopental was added.
Harris et al. [9] administered 500 mg of thiopental to 21 patients immediately before DHCA. The results were recorded before and after the administration of thiopental. The femoral artery was catheterized to measure the arterial blood pressure. The pH and serum electrolytes were also monitored. The results demonstrated an increase in arterial pressure that was positively correlated with an increase in thiopental dose. The pH also rose after the initiation of intravenous thiopental.
Pauca and Roy [10] investigated the effect of thiopental on vascular tone in 250 patients undergoing cardiopulmonary bypass. After the administration of thiopental, the duration and magnitude of hypertension and hypotension were recorded. The study concluded that thiopental produces hypotensive and hypertensive effects by affecting the central nervous system and augmenting the effect of epinephrine, respectively.
Boer et al. [11] reported that thiopentone caused the greatest decrease (78% of control value) in systemic vascular resistance (SVR) compared with etomidate (72% of control value), with propofol producing the lowest decrease in SVR (68% of control value). The duration of the decrease in SVR caused by the administration of thiopentone and etomidate was longer (10 min) than that of propofol (7 min).
Stone et al. [12] infused thiopental in 24 patients undergoing cerebral aneurysm repair that required CPB. He concluded that, in patients with no or minimal cardiac dysfunction, the administration of thiopental does not cause any cardiac damage. He also reported that thiopental loading does not complicate the separation process from CPB.
CLINICAL BOTTOM LINE
The use of thiopental for cerebral protection during circulatory arrest was shown to be effective in both human and animal studies. Furthermore, the timing of thiopental administration is also crucial in preventing cerebral damage. Most of the studies also included other neuroprotective agents and methods alongside thiopental, and the results of such studies provided positive outcomes.
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